Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

They had lower serum 25-hydroxy vitamin D3, GFREPI and were taking more antihypertensive drugs (p < 0.01, respectively).

Source: Baseline characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Associations of parathyroid hormone and atrial fibrillation: epidemiological insights from the LURIC study

Study design awaiting verification · Frontiers in Cardiovascular Medicine · 2026

Original publication title

Associations of parathyroid hormone and atrial fibrillation: epidemiological insights from the LURIC study

L. König; M. R. Grübler; N. Verheyen; E. Kolesnik; M. Wallner; A. J. van Ballegooijen; D. von Lewinski; S. Pilz; A. Tomaschitz; W. März

© 2026 König, Grübler, Verheyen, Kolesnik, Wallner, van Ballegooijen, von Lewinski, Pilz, Tomaschitz and März.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Elevated PTH was associated with prevalent AF in patients referred for coronary angiography after adjustment for common confounders. The association persisted after adjustment for structural, neurohumoral and invasive hemodynamic markers, suggesting that elevated PTH is not merely a surrogate of cardiac dysfunction but may represent an independent correlate of AF. Prospective studies are needed to clarify the temporal and causal relationship between PTH and AF.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Parathyroid hormone (PTH) influences calcium handling in cardiomyocytes and sympathetic cardiac signaling. It has been linked to arterial hypertension and cardiovascular mortality. We hypothesized that PTH is independently associated with atrial fibrillation (AF).

Source: Introduction

Abstract: What methods does the paper describe?

We analyzed data from 3,201 patients (mean age 63 ± 13 years, 25.8% female) enrolled in the LUdwigshafen RIsk and Cardiovascular health (LURIC) study. We defined AF based on medical history or current ECG. Multivariable binary logistic regression was used to assess the association between PTH and AF, adjusting for established AF risk factors, parameters of mineral metabolism, kidney function, and concomitant medication.

Source: Methods

Abstract: Results

AF was present in 389 patients (12.2%). PTH was significantly associated with AF in the primary multivariable model [OR 3.96 (2.32 to 6.76), p < 0.001]. In the fully adjusted model including mineral metabolism and medication variables, the association remained significant [OR 2.32 (1.24 to 4.35), p = 0.009]. The association remained significant after additional adjustment for markers of cardiac dysfunction, including invasive hemodynamic parameters.

Source: Results

Abstract: Conclusion

Elevated PTH was associated with prevalent AF in patients referred for coronary angiography after adjustment for common confounders. The association persisted after adjustment for structural, neurohumoral and invasive hemodynamic markers, suggesting that elevated PTH is not merely a surrogate of cardiac dysfunction but may represent an independent correlate of AF. Prospective studies are needed to clarify the temporal and causal relationship between PTH and AF.

Source: Conclusion
Authors’ abstract

Introduction

Parathyroid hormone (PTH) influences calcium handling in cardiomyocytes and sympathetic cardiac signaling. It has been linked to arterial hypertension and cardiovascular mortality. We hypothesized that PTH is independently associated with atrial fibrillation (AF).

Methods

We analyzed data from 3,201 patients (mean age 63 ± 13 years, 25.8% female) enrolled in the LUdwigshafen RIsk and Cardiovascular health (LURIC) study. We defined AF based on medical history or current ECG. Multivariable binary logistic regression was used to assess the association between PTH and AF, adjusting for established AF risk factors, parameters of mineral metabolism, kidney function, and concomitant medication.

Results

AF was present in 389 patients (12.2%). PTH was significantly associated with AF in the primary multivariable model [OR 3.96 (2.32 to 6.76), p < 0.001]. In the fully adjusted model including mineral metabolism and medication variables, the association remained significant [OR 2.32 (1.24 to 4.35), p = 0.009]. The association remained significant after additional adjustment for markers of cardiac dysfunction, including invasive hemodynamic parameters.

Conclusion

Elevated PTH was associated with prevalent AF in patients referred for coronary angiography after adjustment for common confounders. The association persisted after adjustment for structural, neurohumoral and invasive hemodynamic markers, suggesting that elevated PTH is not merely a surrogate of cardiac dysfunction but may represent an independent correlate of AF. Prospective studies are needed to clarify the temporal and causal relationship between PTH and AF.

Publication and source details

Original title: Associations of parathyroid hormone and atrial fibrillation: epidemiological insights from the LURIC study

L. König; M. R. Grübler; N. Verheyen; E. Kolesnik; M. Wallner; A. J. van Ballegooijen; D. von Lewinski; S. Pilz; A. Tomaschitz; W. März

Frontiers in Cardiovascular Medicine · 2026

* Correspondence: M. R. Grübler martin.gruebler@wienerneustadt.lknoe.at
†

These authors have contributed equally to this work and share first authorship

© 2026 König, Grübler, Verheyen, Kolesnik, Wallner, van Ballegooijen, von Lewinski, Pilz, Tomaschitz and März.2026König, Grübler, Verheyen, Kolesnik, Wallner, van Ballegooijen, von Lewinski, Pilz, Tomaschitz and Märzhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. NV is supported by funding of the Austrian National Bank (Jubilaeumsfonds: project number; 14621). AT is partially funded by the EU Project “MASCARA” [“Markers for Sub-Clinical Cardiovascular Risk Assessment”; THEME HEALTH.2011.2.4.2-2; Grant agreement no: 278249].

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:09:26.523723+00:00

DOI: 10.3389/fcvm.2026.1885117 · PMC13388833